Fermenta Biotech Limited
All news and filings related to Fermenta Biotech Limited.
View all news & filings- Medium impact
Fermenta Biotech inks exclusive Vitamin B12 tech deal with VIT Vellore
Fermenta Biotech has signed an exclusive license agreement with VIT Vellore for Vitamin B12 Fortification Technology. This technology enables natural in-situ enrichment of Vitamin B12 in fermented foods. The collaboration aims to develop scalable solutions for improved nutritional outcomes. The announcement was made on September 8, 2026.
Read the summary - Medium impact
Fermenta Biotech Q1 FY27 Results: Profit Declines, Revenue Steady
Fermenta Biotech reported Q1 FY27 results with standalone revenue at ₹11,183.93 lakh and profit before tax at ₹2,014.58 lakh. Consolidated revenue was ₹12,182.12 lakh and profit before tax was ₹1,469.15 lakh. The results were approved on August 11, 2026.
Read the summary - Low impact
Fermenta Biotech to Meet Investors on September 3, 2026 in Mumbai
Fermenta Biotech Limited will meet with investors on September 3, 2026, in Mumbai. The company will discuss existing press releases and investor presentations, assuring that no unpublished price sensitive information will be disclosed. Changes to the schedule are possible.
Read the summary - Low impact
Fermenta Biotech Publishes Notice for Special Window for Security Transfer
Fermenta Biotech Limited published a notice for a special window for transfer and dematerialisation of physical securities. The notice appeared in Business Standard and Sakal on August 26, 2026, as per SEBI regulations.
Read the summary - Low impact
Fermenta Biotech to Meet Investors on Aug 21
Fermenta Biotech Limited will participate in a one-to-one investor meeting on August 21, 2026, in Mumbai. Press releases and investor presentations will be discussed, available on the company and stock exchange websites. No UPSI will be shared.
Read the summary - Medium impact
Fermenta Biotech Long-Term Rating Upgraded to CARE BBB+; Stable
Fermenta Biotech's credit rating has been upgraded by CARE Ratings. Long-term bank facilities of ₹166.73 crore are now rated CARE BBB+ (Stable), up from CARE BBB (Stable). Short-term facilities of ₹6.25 crore are upgraded to CARE A2 from CARE A3+.
Read the summary - Low impact
Fermenta Biotech Publishes Q1 FY27 Unaudited Financial Results
Fermenta Biotech released its unaudited Q1 FY27 results for the quarter ended June 30, 2026. Consolidated total income was ₹12,619.50 lakh and net profit was ₹953.15 lakh. Standalone total income was ₹11,673.59 lakh and net profit was ₹1,498.58 lakh. The results were published in newspapers on August 12, 2026.
Read the summary - Medium impact
Fermenta Biotech Limited: AGM Voting Results Approved
Fermenta Biotech Limited's 74th AGM on August 11, 2026, saw all resolutions approved. Key approvals include the FY26 financial statements, a ₹3.75 per share dividend, and re-appointment of a director. Members overwhelmingly supported all proposals.
Read the summary - Medium impact
Fermenta Biotech Limited's 74th AGM: All resolutions passed with high majority
Fermenta Biotech Limited's 74th AGM on August 11, 2026, saw all seven resolutions passed with high majority. Key approvals include the adoption of FY26 financial statements and a dividend of ₹3.75 per share. Re-appointment of a director and approval of related party transactions were also confirmed.
Read the summary - Medium impact
Fermenta Biotech's 74th AGM Approves ₹3.75 Dividend, Director Re-appointment, and ₹100 Cr RPT
Fermenta Biotech's 74th AGM on August 11, 2026, approved a dividend of ₹3.75 per share for FY2026, payable by August 21. Ms. Rajeshwari Datla was re-appointed as a Non-Executive Director. Material related party transactions up to ₹100 crores with Fermenta USA LLC were also approved.
Read the summary - High impact
Fermenta Biotech: 74th AGM Presentation Highlights Growth, Innovation, and Financial Strength
Fermenta Biotech reported record FY26 revenue of ₹548 crore, up 14% YoY, with core EBITDA at ₹120 crore and PAT of ₹70 crore. The company secured a plant-source Vitamin D3 patent and an EDQM CEP for D3 100 SD. A ₹110 crore capex is approved for new capacity. Free cash flow tripled to ₹62 crore.
Read the summary - Medium impact
Fermenta Biotech Q1FY27 Investor Presentation Released; Revenue ₹126.2 Crore
Fermenta Biotech's Q1FY27 revenue was ₹126.2 crore. Profit after tax declined 56% YoY to ₹9.5 crore. Human Nutrition revenue grew 24% QoQ. India's contribution to revenue rose to 47%. The company highlighted growth in APIs and Green Chemistry, while Animal Nutrition faced challenges. FSSAI approval for VITADEE Green® was received.
Read the summary - Medium impact
Fermenta Q1FY27 Revenue Flat QoQ at ₹126.2 Cr, Down 13% YoY
Fermenta Biotech's Q1FY27 consolidated revenue was ₹126.2 crore, flat QoQ and down 13% YoY. EBITDA stood at ₹22.4 crore (down 11% QoQ, 39% YoY), and PAT at ₹9.5 crore (down 49% QoQ, 56% YoY). Human nutrition volumes rose 18% QoQ, and India's share in revenue increased to 47%. Post-quarter, VITADEE Green® received FSSAI approval.
Read the summary - Low impact
Fermenta Biotech Approves Unaudited Financial Results for Q1 FY27
Fermenta Biotech's Board approved Unaudited Financial Results for the quarter ended June 30, 2026. Both standalone and consolidated results received an unmodified opinion from auditors.
Read the summary - Low impact
Fermenta Biotech to Meet Investors on August 17, 2026
Fermenta Biotech Limited will participate in a one-to-one investor meeting on August 17, 2026, in Mumbai. No unpublished price sensitive information will be discussed. Details are available on the company's and BSE's websites.
Read the summary - Medium impact
Fermenta Biotech Lists on NSE, Enhancing Market Accessibility
Fermenta Biotech's equity shares are now listed on the NSE effective August 4, 2026. This dual listing on both NSE and BSE aims to increase investor accessibility and market visibility. The company celebrates this milestone in its 75-year journey.
Read the summary
Model portfolios
Filings are the raw material. These are what SEBI-registered experts build from them.
- Stocks
Udaan
Fast-growing, less-covered companies still early in their runway.
Aggressive29 holdings5+ yearsView portfolio - Stocks
Bharat Rising
Built around India's own shifts: capex, household savings, energy and consumption.
Moderate-Aggressive25 holdings3+ yearsView portfolio - Stocks
All-Terrain
One equity portfolio instead of three: large, mid and small cap in a single book.
Moderate-Aggressive34 holdings3+ yearsView portfolio - Stocks
Core Compounders
Companies that have already been through a downturn and came out still growing.
Moderate20 holdings3+ yearsView portfolio